153 related articles for article (PubMed ID: 38772155)
21. [Imeglimin: features of the mechanism of action and potential benefits].
Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
[TBL] [Abstract][Full Text] [Related]
22. Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237539
[TBL] [Abstract][Full Text] [Related]
23. Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages.
Lee JY; Kang Y; Jeon JY; Kim HJ; Kim DJ; Lee KW; Han SJ
J Pharmacol Sci; 2024 Jun; 155(2):35-43. PubMed ID: 38677784
[TBL] [Abstract][Full Text] [Related]
24. A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.
Funazaki S; Yoshida M; Yamada H; Kakei M; Kawakami M; Nagashima S; Hara K; Dezaki K
J Diabetes Investig; 2022 Jan; 13(1):34-41. PubMed ID: 34523242
[TBL] [Abstract][Full Text] [Related]
25. A review of phenformin, metformin, and imeglimin.
Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
27. Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
Nishiyama K; Ono M; Tsuno T; Inoue R; Fukunaka A; Okuyama T; Kyohara M; Togashi Y; Fukushima S; Atsumi T; Sato A; Tsurumoto A; Sakai C; Fujitani Y; Terauchi Y; Ito S; Shirakawa J
Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37314160
[TBL] [Abstract][Full Text] [Related]
28. Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.
Permana H; Soetedjo NNM; Yanto TA; Tendean M; Hariyanto TI; Suastika K
Expert Rev Endocrinol Metab; 2024; 19(1):89-98. PubMed ID: 38047423
[TBL] [Abstract][Full Text] [Related]
29. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.
Vial G; Lamarche F; Cottet-Rousselle C; Hallakou-Bozec S; Borel AL; Fontaine E
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00211. PubMed ID: 33855213
[TBL] [Abstract][Full Text] [Related]
30. Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis.
Kato H; Iwashita K; Iwasa M; Kato S; Yamakage H; Suganami T; Tanaka M; Satoh-Asahara N
Cells; 2024 Feb; 13(3):. PubMed ID: 38334676
[TBL] [Abstract][Full Text] [Related]
31. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
33. Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (-)-epigallocatechin-3-gallate.
Yan J; Feng Z; Liu J; Shen W; Wang Y; Wertz K; Weber P; Long J; Liu J
J Nutr Biochem; 2012 Jul; 23(7):716-24. PubMed ID: 21820301
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
35. The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus.
Ding W; Yang X; Lai K; Jiang Y; Liu Y
Arch Pharm Res; 2024 Mar; 47(3):219-248. PubMed ID: 38485900
[TBL] [Abstract][Full Text] [Related]
36. Imeglimin Hydrochloride: First Approval.
Lamb YN
Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
[TBL] [Abstract][Full Text] [Related]
37. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
Clémence C; Fouqueray P; Sébastien B
Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063
[TBL] [Abstract][Full Text] [Related]
38. Imeglimin in type 2 diabetes.
Huston J; Schaffner H; Langley L; Skrable B; Ashchi A; Berner J; Gore A; Sheikh-Ali M; Sutton D; Goldfaden R
Drugs Today (Barc); 2022 Sep; 58(9):437-449. PubMed ID: 36102904
[TBL] [Abstract][Full Text] [Related]
39. Imeglimin Ameliorates β-Cell Apoptosis by Modulating the Endoplasmic Reticulum Homeostasis Pathway.
Li J; Inoue R; Togashi Y; Okuyama T; Satoh A; Kyohara M; Nishiyama K; Tsuno T; Miyashita D; Kin T; Shapiro AMJ; Chew RSE; Teo AKK; Oyadomari S; Terauchi Y; Shirakawa J
Diabetes; 2022 Mar; 71(3):424-439. PubMed ID: 34588186
[TBL] [Abstract][Full Text] [Related]
40. Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P; Vial G; Fontaine E; Monternier PA; Fouqueray P; Bolze S; Moller DE; Hallakou-Bozec S
Physiol Rep; 2022 Mar; 10(5):e15151. PubMed ID: 35274817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
